Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.70 |
| ▸ | CDK2 | P24941 | 20/20 | 0.70 |
| ▸ | FLT3 | P36888 | 20/20 | 0.70 |
| ▸ | CCNA2 | P20248 | 19/20 | 0.70 |
| ▸ | CCNA1 | P78396 | 19/20 | 0.70 |
| ▸ | JAK1 | P23458 | 2/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.59 |
| ▸ | CCNK | O75909 | 1/20 | 0.59 |
| ▸ | STK10 | O94804 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | PRKCB | P05771 | 1/20 | 0.59 |
| ▸ | CDK1 | P06493 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.59 |
| ▸ | FER | P16591 | 1/20 | 0.59 |
| ▸ | PRKCA | P17252 | 1/20 | 0.59 |
| ▸ | ERCC2 | P18074 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18088687 | 0.96 | JAK2 (0.69) | JAK2CDK2FLT3CCNA2CCNA1 | |
| SCHEMBL18088685 | 0.96 | JAK2 (0.72) | JAK2CDK2FLT3CCNA2CCNA1 | |
| SCHEMBL18088684 | 0.95 | JAK2 (0.71) | JAK2CDK2FLT3CCNA2CCNA1 | |
| SCHEMBL18088686 | 0.91 | JAK2 (0.68) | JAK2CDK2FLT3CCNA2CCNA1 | |
| SCHEMBL18088661 | 0.91 | JAK2 (0.66) | JAK2CDK2FLT3CCNA2CCNA1 | |
| SCHEMBL18088691 | 0.90 | JAK2 (0.66) | JAK2CDK2FLT3CCNA2CCNA1 | |
| SCHEMBL18088766 | 0.90 | JAK2 (0.69) | JAK2CDK2FLT3CCNA2CCNA1 | |
| SCHEMBL19766400 | 0.90 | FLT3 (0.69) | JAK2CDK2FLT3CCNA2CCNA1 | |
| SCHEMBL18088792 | 0.89 | JAK2 (0.64) | JAK2CDK2FLT3CCNA2CCNA1 | |
| SCHEMBL18088694 | 0.88 | JAK2 (0.67) | JAK2CDK2FLT3CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200297724-A1 | COVALENT INHIBITORS OF CDK-7 | NEWAVE PHARMACEUTICAL INC. | 2020-09-24 | — | — | US | disclosed |
| US-10456397-B2 | Covalent inhibitors of CDK-7 | NEWAVE PHARMACEUTICAL INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190151316-A1 | COVALENT INHIBITORS OF CDK-7 | NEWAVE PHARMACEUTICAL LLC | 2019-05-23 | — | — | US | disclosed |
| US-10195200-B2 | Covalent inhibitors of CDK-7 | NEWAVE PHARMACEUTICAL INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180008604-A1 | COVALENT INHIBITORS OF CDK-7 | NEWAVE PHARMACEUTICAL LLC | 2018-01-11 | — | — | US | disclosed |
| WO-2016149031-A1 | COVALENT INHIBITORS OF CDK-7 | NEWAVE PHARMACEUTICAL LLC (US) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10456397-B2 | Covalent inhibitors of CDK-7 | CDK7, CDKL1, CDK1 | JAK2 148/4885CDK2 7/4885FLT3 544/4885 |
| US-20190151316-A1 | COVALENT INHIBITORS OF CDK-7 | CDK7, CDKL1, CDK1 | JAK2 148/4885CDK2 7/4885FLT3 544/4885 |
| US-20200297724-A1 | COVALENT INHIBITORS OF CDK-7 | CDK7, CDKL1, CDK1 | JAK2 148/4885CDK2 7/4885FLT3 544/4885 |
| US-20180008604-A1 | COVALENT INHIBITORS OF CDK-7 | CDK7, CDKL1, CDK1 | JAK2 148/4885CDK2 7/4885FLT3 544/4885 |
| US-10195200-B2 | Covalent inhibitors of CDK-7 | CDK7, CDKL1, CDK1 | JAK2 148/4885CDK2 7/4885FLT3 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.